Luminus Devices Nabs $19M, Aveo Sets IPO Range, Thermo Fisher Scientific Reportedly Makes $6 B Move on Millipore, & More Boston-Area Deals News
(Page 2 of 2)
shareholders to accept a preexisting $5.35 per share offer from the private equity firm Thoma Bravo.
—Cambridge, MA-based e-commerce firm Allurent raised $2 million in its third round of venture capital. Contributors the round, all return investors, included Polaris Venture Partners and a group of angel investors.
—Bloomberg reported that Waltham-based research equipment maker Thermo Fisher Scientific (NYSE: TMO) made an unsolicited $6 billion bid to acquire Billerica, MA-based Millipore (NYSE: MIL), a maker of diagnostic and laboratory equipment.
—Currensee, the Boston-based social network for currency traders, closed an $8 million Series B financing round led by existing investor North Bridge Venture Partners and joined by new investor Egan Managed Capital. Only $6 million of that was new money, as $2 million consisted of Series A funds converted to Series B terms.
—Cambridge-based cancer drug developer Aveo Pharmaceuticals indicated in an SEC filing that it aims to price its planned 7-million-share IPO at $13 to $15 per share.
—Billerica-based biomedical instrument maker Seahorse Bioscience closed a $5 million Series D financing round. Commonwealth Capital Ventures, Rock Maple Ventures, Life Sciences Partners, FLIR Systems, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures, and HLM Venture Partners contributed to the round.
—LED maker Luminus Devices, also of Billerica, raised $19 million in Series F funding from return investors including Argonaut Private Equity, Braemar Energy Ventures, Paladin Capital Group, and Stata Venture Partners.